Maternal vitamin A deficiency appears to be widespread in low-income countries. Currently, the World Health Organization estimates nearly 20 million pregnant women to be vitamin A deficient, exhibiting a serum retinol concentration below 0.70 μmol/L, of whom nearly 9 million have gestational night blindness, an ocular manifestation of deficiency.
1 Night blindness during pregnancy is associated with increased risks of maternal anemia, morbidity, and mortality,
2,3 suggesting that preventing vitamin A deficiency could improve maternal survival. Evidence of such an effect has been reported in rural Nepal, where a randomized controlled trial demonstrated a decrease of approximately 44% in mortality related to pregnancy following continuous, weekly receipt of vitamin A or beta carotene during the reproductive years at dosages approximating a recommended daily allowance.
4 The reduction was most apparent in women with night blindness,
3 and causes of death attenuated in risk were those involving infectious, obstetric, and miscellaneous causes as determined by interviews with family members.
4 Supplementation also modestly decreased reported symptoms of morbidity.
5 Plausible host defenses against severe illness, which likely rely on vitamin A–regulated cell proliferation and differentiation and could be compromised by vitamin A deficiency, include multiple mechanisms of epithelial innate and adaptive immunity,
6 hematopoiesis,
7,8 and coagulation,
9 abnormalities of which could exacerbate infection, result in anemia, or impair wound recovery.
9 Although in a trial conducted in Nepal there was no overall effect on infant mortality,
10 there was evidence of a reduction in mortality among infants born to mothers with a positive history of gestational night blindness.
11